Clinical porcine islet xenotransplantation under comprehensive regulation.

Abstract

BACKGROUND:

Xenotransplantation with porcine islets is a promising approach to overcome the shortage of human donors. This is the first report of phase 1/2a xenotransplantation study of encapsulated neonatal porcine islets under the current framework of regulations for xenotransplantation in New Zealand.

METHODS:

Newborn piglets were anesthetized and bled, and the pancreata were removed with the use of sterile technique and processed. Encapsulated neonatal porcine islets were implanted with the use of laparoscopy into the peritoneal cavity of 14 patients with unstable type 1 diabetes without any immunosuppressive drugs. The patients received encapsulated islets of 5,000 (n = 4; group 1), 10,000 (n = 4; group 2), 15,000 (n = 4; group 3), or 20,000 (n = 2; group 4) islet equivalents per kg body weight. Outcome was determined from adverse event reports, HbA1c, total daily insulin dose, and frequency of unaware hypoglycemic events. To assess graft function, transplant estimated function (TEF) scores were calculated. Sufficient or marginal numbers of encapsulated neonatal porcine islets were transplanted into streptozotocin-induced diabetic B6 mice as an in vivo functional assay.

RESULTS:

There were 4 serious adverse events, of which 3 were considered to be possibly related to the procedure. Tests for porcine endogenous retrovirus DNA and RNA were all negative. The numbers of unaware hypoglycemia events were reduced after transplantation in all groups. Four of 14 patients attained HbA1c <7% compared with 1 at baseline. The average TEF scores were 0.17, 0.02, -0.01, and 0.08 in groups 1, 2, 3, and 4 respectively. The in vivo study demonstrated that a sufficient number of the transplanted group reversed diabetes with positive porcine C-peptide.

CONCLUSIONS:

Transplantation of encapsulated neonatal porcine islets was safe and was followed by a reduction in unaware hypoglycemia events in unstable type 1 diabetic patients. The mouse in vivo assessment data demonstrated certain graft function.

• Authors: S Matsumoto, P Tan, J Baker, K Durbin, M Tomiya, K Azuma, M Doi, R B Elliott
• Journal: Transplantation proceedings (Transplant Proc) 2014 Jul-Aug Vol. 46 Issue 6 Pg. 1992-5 ISSN: 1873-2623 [Electronic] United States
• PMID: 25131091 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article)
• Copyright: Copyright © 2014 Elsevier Inc. All rights reserved.

Chemical References

• C-Peptide
• Glycated Hemoglobin A
• Hypoglycemic Agents
• Insulin

Topics

• Animals
• Animals, Newborn
• C-Peptide (blood)
• Diabetes Mellitus, Experimental (surgery)
• Diabetes Mellitus, Type 1 (complications, drug therapy, surgery)
• Female
• Glycated Hemoglobin (metabolism)
• Humans
• Hypoglycemia (etiology, prevention & control)
• Hypoglycemic Agents (therapeutic use)
• Insulin (therapeutic use)
• Islets of Langerhans Transplantation (methods)
• Male
• Mice
• Middle Aged
• New Zealand
• Swine
• Transplantation, Heterologous (methods)
• Treatment Outcome